Magazine
Events, news and scientific publications

Three Days in Milan: Noventure at CPHI 2026
Noventure took part in CPHI Milan 2026, where our team met partners and distributors at stand 20K1 to discuss licensing opportunities for our barrier-based portfolio.

Four Days in Lille: Noventure at ESPGHAN 2026
Last week, Noventure took part in the 58th Annual Meeting of ESPGHAN in Lille, France, where our team presented the Tasectan® paediatric range to clinicians from across Europe and beyond.

Utipro® Plus AF Named Best Women’s Product at the OTC Awards 2026
Utipro® Plus AF has been named Best Women’s Product at the OTC & Retail Pharmacy Product Awards 2026 in Ireland, collected by our partner Pamex Limited.

Tasectan and Xilaplus in the new German GPGN Guidelines
Z Gastroenterol 2024; 62(09): 1574-1643 Getting into treatment guidelines is lengthy, especially for new products that need time to gather sufficient scientific
New publication on good results with EHO-85 hydrogel compared to products commonly used in wound healing.
Olive tree (Olea europaea) leaf extract (OELE) has important antioxidant and anti-inflammatory properties, supporting its use in human clinical practice (1). A

Publication on the antioxidant and wound-healing properties of EHO-85
The excess of free radicals in the wound environment contributes to its stagnation during the inflammatory phase, favouring hard-to-heal wounds. Oxidative stress

Partner Devicare, S.L.
We would like to announce our new partnership with Devicare, S.L., to bring Utipro Plus AF into the Spanish market! We’re excited

New publication on hydrogel EHO-85 in anal fissures
Last July 2024, information from the Journal of Wound Management, the official journal of the European Society of Wound Management (EWMA), was

New Publication on hydrogel EHO-85 in difficult-to-heal wounds
Chronic wounds, especially those that are hard-to-heal, constitute a serious public-health problem. To evaluate the superiority of a hydrogel (EHO-85), containing Olea

Tasectan MDR Approved
GREAT NEWS! Noventure is delighted to announce that our medical device Tasectan has just been granted a new CЄ Certificate under MDR
UTIPRO® PLUS AF reaches Central Asia
We are happy to inform that Utipro® Plus AF is ready to land in Central Asia thanks to its very recent registration
New publication for UTIPRO® PLUS / UTIPRO® PLUS AF (The UTISWISS Study)
We are happy to announce the publication of new evidence on the benefit of an antibiotic-free approach (xyloglucan, hibiscus and propolis for
New publication on the benefits of our hydrogel EHO-85 containing olive leaves extract in accelerating early wound healing.
A sub-analysis of previous clinical trial (1) conducted with the EHO-85 hydrogel in the treatment of patients with pressure ulcers, venous ulcers
New publication on Recurrent UTI: Q&A on Clinical Practice1
A novel mode of action to promote antibiotic-sparing approach to Recurrent UTIs: Questions and Answers on Clinical Practice1 Consultations for recurrent urinary
New publication on the mode of action of Mucoprotectants: gelatin tannate and xyloglucan show similar effectivity on preventing Cholera Toxin-Induced diarrhea in experimental studies1
The newer antidiarrheal agents include the mucoprotectants gelatin tannate and xyloglucan. Both were able to attenuate cholera toxin-induced intra-loop water secretion in
New publication for Utipro® Plus / Utipro® Plus AF
Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of
Second publication for OLE hydrogel
After the publication of the first paper in which the significant antioxidant activity of Olea europaea leaf extract (OELE) was observed and assessed, we
Publication of first clinical evidence for EHO-85 hydrogel
The first clinical evidence related to an hydrogel based on Olea europaea leaf extract (EHO‐85) indicated for the healing of wounds of full and partial thickness has been
Impact of Covid-19 on UTI and antibiotic stewardship (T. Cai et al. on Uro 2022)
Several recent studies showed that, despite the overall percentage of bacterial co-infection among COVID-19 patients was low, the use of antibiotic was
First publication for OLE hydrogel
We are happy to announce the publication in Pharmaceutics of the first paper related to our hydrogel based on Olea europaea leaf extract (OELE) indicated for the healing of wounds of
First launch of UTIPRO® PLUS AF in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in Portugal. Portugal is the first European country in which UTIPRO®

Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically
UTIPRO® PLUS AF strengthens its presence in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in the Republic of Ireland. UTIPRO® PLUS AF, in its composition
We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children”
Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol:
Uncomplicated Urinary Tract Infection in Adults – Noventure new Publication
We are glad inform you about a recent publication to further support the usefulness of mucoprotection in the relief of symptoms and

Gelatin tannate versus other antidiarrheal medication in children with acute gastroenteritis: a retrospective, observational study
Elena D Serban & Mihai Manolache; Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Journal of Comparative Effectiveness ResearchVol. 8, No. 3

A randomized controlled trial comparing a xyloglucan-based nasal spray with saline in adults with symptoms of rhinosinusitis.
Allegrini A et al. Current Medical Research and Opinion 2017. June 10: 1-17 Background: This study assessed the efficacy, safety and tolerability

Congresses: Noventure participates at the third edition of FNM
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology

AGA Abstracts Tu1254 – Protective Effect of Mucoprotectants and Prebiotic Combination on Gut Barrier Impairment and Visceral Hypersensitivity Induced by an Acute Stress in Rat
HeleneEutamene, FannyPlacide, ValerieTondereau, VassiliaTheodorou https://doi.org/10.1016/S0016-5085(18)33080-4 BACKGROUND: Irritable Bowel Syndrome (IBS) is a common disorder characterized by visceral hypersensitivity and increased intestinal permeability.

Rhinosectan® Launched In Spain
We are pleased to announce the launch of Rhinosectan® in its first market, Spain. Rhinosectan® is based on Xyloglucan, a mucomimetic agent

The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.
Octavian Alexea, Vlad Bacarea and Nuria Pique. United European Gastroenterol J. 2016 Jun;4(3):455-65. Background: A medical device containing the film-forming agent reticulated

Gelatin Tannate for Acute Childhood Gastroenteritis: A Randomized, Single-Blind Controlled Trial.
Maurizio Mennini1,Carlo Tolone, Antonella Frassanito, Fabio Midulla3, Salvatore Cucchiare, Marina Aloi. Paediatr Drugs. 2016 Dec 20. doi: 10.1007/s40272-016-0207-z Background: Oral rehydration therapy

A new class of non-drug treatments for rhinitis of various origins is gaining momentum. Among them, Xyloglucan stands out as a natural substance with a well-defined mode of action…
A new class of non-drug treatments for rhinitis of various origins is gaining momentum. Among them, Xyloglucan stands out as a natural
Listado de investigadores
Centros de investigación participantes en el ensayo
clínico con el hidrogel EHO-85
“Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”
Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann
Partner Medexport – Utipro Plus AF – Kazakhstan
Noventure is proud to announce that Medexport has signed an agreement for the distribution of Utipro Plus AF in Kazakhstan We are
Partner Pamex UK
Glad to inform that Noventure partnership with the Irish partner Pamex is growing! We are really happy to announce that Pamex is
Launch of TASECTAN® AF in Denmark
Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market,
UTIPRO® PLUS Launched in Denmark
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Denmark. The product is commercialized under

Launch of TASECTAN® AF in Finland and Sweden
Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland and Norway.
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is
New publication for Utipro® Plus
New publication for Utipro® Plus We are pleased to announce the publication of a case series referring about the benefits of Utipro®

Utipro® Plus Webinar session
We are pleased to inform you about our first #webinar sessions❗ On October 30th we talked about #UTIPROPLUS and its use in
A new publication confirms the role of xyloglucan as a mucosa protector in the management of urinary tract infections
Esposito E et al. Effect of xyloglucan against Escherichia coli extraintestinal urinary tract infection: an in vivo study. Microb Physiol. Published online:
Urinary tract infections in the elderly: a review of disease characteristics and current treatment options
Rodriguez-Mañas L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs in Context 2020; 9:
Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study.
Cai T et al. Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study. Future Microbiol.

Utipro® Plus AF available for launch
Utipro® Plus AF available for launch We are pleased to announce the availability for launch of a new formulation of UTIPRO® PLUS,
UTIPRO PLUS® launched in Finland
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Finland. The product is commercialized over

News on NOVENTURE participation at EAU 2019 in BARCELONA
News on NOVENTURE participation at EAU 2019 in BARCELONA For the fourth consecutive year, Noventure was present at the annual congress of

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview
Int. J. Mol. Sci. 2018, 19(3), 673 Abstract Disruption of the epithelial barrier function has been recently associated with a variety of
TASECTAN® launched in Croatia by JGL
TASECTAN® launched in Croatia by JGL. Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL,

Xilaplus® launched in France by Therabel
Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée.
Efficacy of gelatin tannate for acute diarrhea in children: a systematic review and meta-analysis.
Aloi M, Mennini M. J Comp Eff Res. 2018 Nov 22. Efficacy of gelatin tannate for acute diarrhea in children: a systematic
Rhinosectan® spray (containing xyloglucan) on the ciliary function of the nasal respiratory epithelium; results of an in vitro study
Allergy, Asthma & Clinical Immunology2018 Abstract: Background To assess the effects of Rhinosectan® spray, a medical device containing xyloglucan, on nasal ciliary function
New scientific publication on RHINOSECTAN®
De Servi B et al. Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results

News on NOVENTURE participation in 2018 EAACI in Munich
Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018
As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key

New scientific evidence reinforces usefulness of the mucoprotective approach
M. Lanza1, I. Paterniti1, M. Campolo1 ,G. Casili1 , A. Filippone1,A. Peritore1, S. Cuzzocrea1,2 ,E. Esposito1 1Department of Chemical, Biological, Pharmaceutical and

Noventure’s Participation in 2018 EAU congress
For the third consecutive year, Noventure has participated in the annual congress of the EAU – European Association of Urology that took

Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually.
Thorpe KE, Joski P, Johnston KJ. Health Aff (Millwood) 2018 Apr;37(4):662-669. doi: 10.1377/hlthaff.2017.1153. Epub 2018 Mar 21. Abstract Antibiotic-resistant infections are a global

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®
Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in
Noventure welcomes new partners to expand the presence of its products in new territories.
We are pleased to announce that we are expanding the international coverage of our products thanks to the recent signature of agreements

Corporate Press Release: Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis
Barcelona, Spain, February 22, 2018 – Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which

New scientific publication on Mucoprotection and diarrheal processes.
Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6 Expert Opin Investig

Utipro® Plus Launched In France
We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is

Utipro® Plus Launched In Israel
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is

Tasectan® Duo launched in Austria
We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Duo´s second

The role of mucoprotectants in the management of gastrointestinal disorders.
Eutamene, Beaufrand Harkat C, Theodorou V. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018 ABSTRACT Introduction: The intestinal barrier controls the absorption of

New Scientific publication on TASECTAN® DUO
Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct

New scientific communication on UTIPRO® PLUS
Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract

New partnership: Xilaplus® AF in Turkey
New partnership: Xilaplus® AF in Turkey Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF
Management of acute diarrhoea
Annamaria Staiano Italian Journal of Pediatrics 2017, 43(Suppl 1): A2 Diarrhoea in children still has a major impact on health-related social costs,
Irritable Bowel Syndrome
Ford et al. N Engl J Med 2017; 376:2566-78 New article in NEJM supports the role of increased intestinal permeability in the
Noventure’s participation to 2017 EAU
European Association of Urology – London 25th – 27th March 2017. More than 10.300 total participants, coming from 113 countries all over
Corporate Press Release: Noventure and RFSU enter into agreement to commercialize Utipro® Plus across Nordic countries.
Barcelona, March 13, 2017 – Noventure and Riksförbundet för sexuell upplysning (RFSU), the Swedish Association for Sexuality Education, announce today that they
Effect of Utipro® (containing xyloglucan-gelatin) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study.
De Servi B et al. Future Microbiology. Published on line: 29 March 2016 Aim: To evaluate whether Utipro(®), a natural product approved
Undissociated Gelatine Tannate reduces intestinal leakiness and mucosa inflammation by forming a protective biofilm: results from in-vitro and in-vivo studies.
L. Bueno et al. UEG Journal – United European Gastroenterology Journal, Oct.2013: Vol. 1, Supl. 1; ISSN 2050-6406 (print) ISSN 2050-6414 (online) –
New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 1: film-forming effect.
Freli V. et al. Presented at GFHGHP 2012. Presented as oral communication at the 33rd edition of the Congress from the Groupe
Intestinal goblet cells and mucins in health and disease: recent insights and progress.
Kim YS, Ho SB. Curr Gastroenterol Rep. 2010 Oct;12(5):319-30 The mucus layer coating the gastrointestinal tract is the front line of innate
The outer mucus layer hosts a distinct intestinal microbial niche
Hai Li, Julien P. Limenitakis, Tobias Fuhrer, Markus B. Geuking, Melissa A. Lawson, Madeleine Wyss, Sandrine Brugiroux, Irene Keller, Jamie A. Macpherson,
New publication on Tasectan Duo
L. Lopetuso, C. Graziani, A. Guarino, A. Lamborghini, S. Masi, V. Stanghellini Eur Rev Med Pharmacol Sci . 2017; 21 (4): 873-883
Gelatin Tannate: A Selective Biofilm-forming, Gut Mucoprotectant for Acute Gastroenteritis in Children. A Short Narrative Review.
Jess Torres-Herrera, and Gabriel Torres-Ruiz. Current Drug Therapy, 2017, 12, 1-6 Background: Gelatin tannate is bowel selective, safe and effective, and acts
Scientific publicationRegulation of tight junctions in upper airway epithelium.
Takashi Kojima, Mitsuru Go, Ken-ichi Takano, Makoto Kurose, Tsuyoshi Ohkuni, Jun-ichi Koizumi, Ryuta Kamekura, Noriko Ogasawara, Tomoyuki Masaki, Jun Fuchimoto, Kazufumi Obata,
Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea.
L. Lopetuso, C. Graziani, A. Guarino, A. Lamborghini, S. Masi, V. Stanghellini Eur Rev Med Pharmacol Sci . 2017; 21 (4): 873-883
Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.
Catalin Pleasea Condratovici, Xavier Llop, Núria Piqué, Vladimir Bacarea. 23rd UEG WEEK BARCELONA. October 24-28 2015
Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, clinical trial
Catalin Pleasea Condratovici, Vladimir C. Bacârea, Núria Piqué. Gastroenterology Research and Practice. April 2016 Background: Xyloglucan, a film-forming agent, improves intestinal mucosa
The effect of gelatin tannate in acute diarrhea in children.
Soner Sertan Kara, Burcu Volka2, Ibrahim Erten. G-eP-020. ESPGHAN 50th Annual Meeting – Abstracts. May 2017. Pag 114 Objectives and study: Acute
Evaluation of Gelatin Tannate Against Symptoms of Acute Diarrhea in Pediatric Patients.
Çağan E, Ceylan S, Mengi Ş, Çağan HH. Med Sci Monit. 2017 Apr 27;23:2029-2034. Background: Acute diarrhea is the second most common
Efficacy and safety of gelatine tannate for the treatment of acute gastroenteritis in children: protocol of a randomised controlled trial.
Michałek D, Kołodziej M, Konarska Z, Szajewska H. BMJ Open. 2016;6(2):e010530. doi:10.1136/bmjopen-2015-010530. Introduction: Worldwide, acute gastroenteritis in children, usually caused by viruses,
Gelatin tannate as treatment for acute diarrhea in children: a prospective, randomized, parallel study.
M. Aloi , F. Pofi, C. Tolone, M. Piccirillo , A. Nicolai , G. Romano, G. D’Arcangelo, S. Cucchiara. Abstracts / Digestive
Severe Diarrhea in a 4-month-old baby girl with acute gastroenteritis: a case report and review of the literature.
Guzganu I. Case Reports in Gastrointestinal Medicine, Volume 2012. A 4.5-month-old baby girl presented to hospital with a 2-day history of watery
Tasectan (gelatine tannate) for the treatment of acute gastroenteritis in children: Preliminary results from a study conducted to evaluate its efficacy and safety.
Allegrini A. et al. Poster published at the 39th annual paediatric Belgium society congress, Brussels, March 2011 (Poster publication)
A comparative analysis of response to ORS (oral rehydration solution) vs. ORS + gelatine tannate in two cohorts of paediatric patients with acute diarrhoea.
Carretero et al. Rev. Esp. Enferm. Dig, Vol.101 Nº1, pp. 41-48, 2009. Aim: the study aims to observe the response to treatment
Prospective Observational Study on Infants and children with Acute Diarrhoea treated with gelatine tannate.
Durban Reguera F. et al. Presented as a poster in the congress “Semana de las Enfermedades Digestivas” in Madrid (Spain), June 2007.
Glycans as legislators of host–microbial interactions: spanning the spectrum from symbiosis to pathogenicity.
Lora V. Hooper Jeffrey I. Gordon Glycobiology (2001) 11 (2): 1R-10R. The number of microbes associated with our gut likely exceeds our
Evaluation of reticulated gelatin-hibiscus-propolis against intestinal commensal species commonly associated with urinary tract infections. Future Microbiology. Published online: 3 March 2017
Olier M et al. Future Microbiology. Published online: 3 March 2017 Aim: Reticulated gelatin (RG), hibiscus and propolis (RGHP) is a medical
Antibiofilm polysaccharides.
Rendueles O1, Kaplan JB, Ghigo JM. Environ Microbiol. 2013 Feb;15(2):334-46. Bacterial extracellular polysaccharides have been shown to mediate many of the
Allergy as an epithelial barrier disease
Pirkko Mattila, Sakari Joenväärä, Jutta Renkonen, Sanna Toppila-Salmi and Risto Renkonen Clinical and Translational Allergy20111:5 The objective of this review is
Regulation of Tight Junction Permeability by Intestinal Bacteria and Dietary Components
Dulantha Ulluwishewa, Rachel C. Anderson, Warren C. McNabb, Paul J. Moughan, Jerry M. Wells, and Nicole C. Roy. J. Nutr. May 1,
Gelatine Tannate for the treatment of Acute Diarrhoea in Adults.
Allegrini A. & Constantini M. J Gastroint Dig Syst 2012, 2:3. Abstract: Gelatine tannate has been recently licensed as a medical device
Prospective Observational Study on Adults with Acute Diarrhoea treated with gelatine tannate.
Durban Reguera F. et al. Presented as a poster in the congress “Semana de las Enfermedades Digestivas” in Madrid (Spain), June 2007.
New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 2: antibacterial activity.
De Servi B, et al. Presented at GFHGHP 2012. Presented as oral communication at the 33rd edition of the Congress from the

Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiology. Published online: 27 Feb 2017
Guglietta A. Future Microbiology. Published online: 27 Feb 2017 Urinary tract infections(UTIs) are one of the most common bacterial infections in
Tight Juction-related human diseases
Norimasa Sawada Pathology International Tight junctions are intercellular junctions adjacent to the apical ends of paracellular spaces. They have two classical
The mucosal barrier at a glance
Marion M. France, Jerrold R. Turner J Cell Sci 2017 (Journal of Cell Science) Mucosal barriers separate self from non-self and
Biopolymeric Mucin and Synthetic Polymer Analogs: Their Structure, Function and Role in Biomedical Applications.
Sundar P. Authimoolam and Thomas D. Dziubla Polymers 2016, 8(3), 71 Mucin networks are viscoelastic fibrillar aggregates formed through the complex
Tight junctions: from simple barriers to multifunctional molecular gates.
Zihni C1, Mills C1, Matter K1, Balda MS1. Nat Rev Mol Cell Biol. 2016 Sep;17(9):564-80. doi: 10.1038/nrm.2016.80. Epub 2016 Jun 29. Epithelia
Glycoconjugates and Glycomimetics as Microbial Anti-Adhesives
Sara Sattin, Anna Bernard Cell Press, Volume 34, Issue 6, p483–495, June 2016 Microbial adhesion is an essential step in infection
Barrier-enforcing measures as treatment principle in allergic rhinitis: a systematic review.
Andersson M, Greiff L, Ojeda P, Wollmer P. Curr Med Res Opin. 2014 Jun;30(6):1131-7. doi: 10.1185/03007995.2014.882299. Epub 2014 Jan 30.2:3. Background and
The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors.
L.R. Lopetuso, F. Scaldaferri, G. Bruno, V. Petito, F. FranceschI, A. Gasbarrini. European Review for Medical and Pharmacological Sciences. 2015; 19: 1068-1076
Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.
Lucio Gnessi, Xavier Llop, Núria Piqué. 23rd UEG WEEK BARCELONA. October 24-28 2015
Undissociated gelatine tannate and xyloglucan prevent gut leakiness and mucosal inflammation induced by LPS: insights in the mechanism of action.
H. Eutamene. P1449. UEG journal. October 2016. Vol 4. Suppl. 1 Pag A651 Introduction: Gelatine tannate (GT) and xylogucan (XG) are commercially available
A new approach to the treatment of uncomplicated cystitis: results of a randomized placebo-controlled clinical trial.
Salvatorelli N et al. Urologia Internationalis. Published on line: April 8, 2016 Objective: To assess the efficacy and safety of a new
Efficacy and safety of a medical device versus placebo in the early treatment of patients with symptoms of urinary tract infection: a randomized controlled trial.
García-Larrosa A et al. Clinical Microbiology 2016, 5:1 Background: The objective of the study was to analyze the efficacy and safety of
Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.
Fraile B et al. Future Microbiology. Published online: 27 March 2017 Aim: To assess the properties of a medical device containing xyloglucan,
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for ‘gut barrier protectors’ in IBD?
Franco Scaldaferri Loris Riccardo Lopetuso1, Valentina Petito, et al. United European Gastroenterology Journal 2014, Vol. 2(2) 113–122 Background: Gelatin tannate, a gelatin
Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.
Lucio Gnessi, Vladimir Bacarea, Marius Marusteri and Núria Piqué. BMC Gastroenterology (2015) 15:153 Background: There is a strong rationale for the use

euroPLX 88
Lisbon, Portugal 2-3 June 2025 Noventure will attend the euroPLX-88 to be held in Lisbon, Portugal 2-3 June 2025. Arrange a meeting

ESPGHAN 2025
Helsinki, Finland, 14-17 May 2025 Noventure will attend the 57th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition

Vitafoods 2025
Barcelona, Spain, 20-22 May 2025 Noventure will attend Vitafoods to be held in Barcelona, 20-22 May 2025 Arrange a meeting with us

Europharm International Business Meeting 2025
Athens, Greece, 10-11 April 2025 Noventure will attend Europharm, in Athens, Greece, on 10-11 April 2025. Arrange a meeting with us to


Vitafoods 2024
Geneva, Switzerland, 14-16 May 2024 Noventure will attend Vitafoods to be held in Geneva, 14-16 May 2024 Arrange a meeting with us


Nutraceuticals
Barcelona, Spain, 6-7 March 2024 Noventure will attend Nutraceuticals, to be held in Barcelona, Spain, 6-7 March 2024. Arrange a meeting with

euroPLX 84
Cascais, Lisbon, 26-27 February 2024 Noventure will attend the euroPLX-84 to be held in Cascais, Lisbon, 26-27 February 2024. Arrange a meeting

euroPLX 83
Vienna, Austria, 25-26 September 2023 Noventure will attend the euroPLX-83 to be held in Vienna, Austria, 25-26 September 2023. Arrange a meeting

PharmaSynergy OTC
Milan, Italy, 14-15 September Noventure will attend the PharmaSynergy OTC to be held in Milan, Italy, 14-15 September 2023. Arrange a meeting with



ESPGHAN 2023
Vienna, Austria, 17-20 May Noventure will attend the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN),

Vitafoods 2023
2023, May 9-11 Geneva, Switzerland Noventure will attend the Vitafoods 2023 to be held in Geneva, 9-11 May 2023. Arrange a meeting

euroPLX 82
Noordwijk, Netherlands, 12-13 June Noventure will attend the euroPLX-82 to be held in Noordwijk, Netherlands, 12-13 June 2023. Arrange a meeting with us

Europharm 2023
Lisbon, Portugal, 20-21 April Noventure will attend the EuropharmSMC International Business Meeting 2023, that will take place in Lisbon on 20-21 April

euroPLX 2023
Cascais, Lisbon, 20-21 March Noventure will attend the euroPLX 2023 to be held in Cascais, Lisbon, 20-21 March 2023. Arrange a meeting with



Gastro Update Europe 2019
2019, JUNE 14-15 BUDAPEST, HUNGARY NOVENTURE will be present at Gastro Update Europe 2019, in Budapest, June 14 – 15, 2019. Visit us


PharmaVenue Palma de Mallorca
2017, NOV 23-24 Palma de Mallorca, Spain NOVENTURE will be present at PharmaVenue in Palma de Mallorca. Arrange a meeting with us to learn

UEGWeek 2017 – The 25th United European Gastroenterology Week
October 28 – November 1, 2017 Venue: Fira Gran Vía. BARCELONA, SPAIN NOVENTURE will be present at UEG week 2017. Come meet

NeuroGASTRO 2017: event organised by The European Society of Neurogastroenterology and Motility (ESNM)
2017, AUGUST 24-26 CORK, IRELAND NOVENTURE will be present at NeuroGastro 2017. Come meet us at our booth number 9 to discover our
Congresses
Let’s meet in…
6–8Oct 2026CPHI 2026Milan, ItalyVisit the congress website
24Jun 2026ESPGHAN 2026Lille, FranceVisit the congress website
28Oct 2025CPHI 2025Frankfurt, GermanyVisit the congress website
Recent on LinkedIn
We’re pleased to welcome Clementina Vidal de Arana to Noventure as our new Business Operations & HR Manager.
We’re very happy to welcome Elisenda Gendra PhD MSc to the Noventure team as Head of Regulatory Affairs & Quality, Technical Director, and PRRC.
We’re excited to announce that Noventure will be at CPHI Milan 2026, from October 6–8.
